Dataset from A Phase II, Multicenter, Long-term Extension Study to Compare the Safety and Efficacy of TAK-385 (10, 20, and 40 mg) Following Oral Administration for 12 Weeks or More in the Treatment of Endometriosis
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009883
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to compare the long term safety and efficacy of TAK-385, once
daily (QD) following continued administration in participants who completed a Phase II
dose-finding study.
创建时间：
2025-02-10
